23:47 , Aug 17, 2017 |  BC Week In Review  |  Clinical News

Japan approves Mitsubishi's Canalia for Type II diabetes

Last month, Mitsubishi Tanabe Pharma Corp. (Tokyo:4508) and Daiichi Sankyo Co. Ltd. (Tokyo:4568) said Japan's Ministry of Health, Labor and Welfare (MHLW) approved Canalia teneligliptin/canagliflozin (MT-2412) to treat Type II diabetes. Canalia is an oral fixed-dose...
22:38 , Apr 6, 2017 |  BC Week In Review  |  Company News

Mitsubishi Tanabe Pharma, Daiichi deal

Mitsubishi Tanabe and Daiichi partnered to commercialize Mitsubishi's MT-2412 to treat Type II diabetes. Daiichi will market MT-2412 and both companies will co-promote the compound, which is under review in Japan. MT-2412 is an oral...